Table 2B.

b) Characteristics of the transplantation and outcome.
Patient	Year of transplant	Age at transplant	Mobilization	Conditioning regimen	Complications before D100	OR	FU in this study(months)	Case previously published (FU reported in months)
1	1999	33	G-CSF	iCYC+ATG		CR	48	No
2	1999	49	iCYC + G-CSF	Melphalan	Fever of unknown origin	CR	252	Yes (96)
3	1999	31	iCYC + G-CSF	Melphalan	Fever of unknown origin	CR	252	Yes (72)
4	Before 2002	26	iCYC + G-CSF	BEAM		CR	48	Yes (48)
5	Before 2002	26	iCYC + G-CSF	BEAM		CR	48	Yes (48)
6	2002	30	iCYC + G-CSF	BEAM		NR	6	No
7	2011	49	iCYC + G-CSF	iCYC+ATG		DDPR*	48	No
8	2009	29	iCYC + G-CSF	Melphalan		CR*	24	No
9	2016	42	iCYC + G-CSF	Melphalan	Pneumonia (Rhinovirus + Klebsiella Pneumoniae), AF, Line-DVT, Depression	CR*	37	No
10	2016	51	iCYC + G-CSF	Melphalan	Pneumonia	CR	96	No

*Relapse.

AF, Atrial Fibrillation; ATG, Anti Thymocyte Globulin; BEAM, Bicnu, Etoposide, Aracytine, Melphalan; CR, Complete Remission: no evidence for disease activity in patients with daily prednisolone equivalent dosage ≤ 7.5mg and absence of disease-modifying drugs; DDPR, Drug- Dependent Partial Response = any documented clinical and/or laboratory response in patients receiving glucocorticoids ≥7.5mg daily prednisolone dosage and/or disease modifying drugs; DVT, Deep Venous Thrombosis; iCYC, intravenous Cyclophosphamide; G-CSF, Granular Colony Stimulating Factor; NR, No Response; OR, Overall Response.